radiation therapy (IORT) was used as part of the initial therapy for malignant glioma in 32 of 73 patients with histologically verified anaplastic astrocytoma (grade III astrocytoma) and glioblastoma multiforme. The initial treatment for all cases was subtotal or total tumor resection com bined with external irradiation and chemotherapy. IORT was performed 1 week after tumor resection, with doses of 10-50 Gy (mean 26.7 Gy) in one session. Fourteen of 32 cases had IORT two times because of tumor recurrence. The IORT patients had survival rates at 24 and 36 months after initial treatment of 57.1 and 33.5% (median survival 26.2 months). The other 41 patients had 23.6 and 13.1 % survivals (median survival 20.7 months), which were significantly lower (p &lt; 0.01). Tumor recurrence within the original lesion site was suspected because of clinical condition, computed tomography, and magnetic resonance imaging studies in 65.6% of the IORT group (21 cases) 12 months after initial treatment. Twenty cases of death in the IORT group, including five autopsy cases, demonstrated regional tumor recurrence with a high incidence of intraventricular tumor invasion. The authors con sider IORT is beneficial for selected malignant glioma patients, including tumor recurrence, because of prolonged survival.
Introduction
Malignant glioma such as anaplastic astrocytoma and glioblastoma multiforme has a high incidence of recurrence at the primary lesion site after opera tion and irradiation.
This pattern of local recur rence has encouraged the introduction of various new treatments for local disease. Intraoperative radiation therapy (IORT) is one such method rare ly used.9°101 IORT delivers high radiation doses at the residual tumor bed after surgery with minimal damage to the surrounding normal brain tissue.
Here, we discuss our investigation of IORT as part of the initial therapy for malignant glioma evaluated by the survival of patients receiving IORT.
Clinical Materials and Methods
Our series included 73 patients with malignant glioma treated between 1982 and 1989. There were 45 males and 28 females, ranging in age from 13 to 78 years (mean 45.7 years). The Karnofsky performance status before initial operation ranged from 60 to 100% (median 74.6%). The tumor sites identified by both preoperative computed tomographic (CT) scan and surgical findings were frontal lobe in 27 cases, temporal lobe in 31, parietal lobe in 12, and oc cipital lobe in three. The tumor size on postcontrast CT scan ranged from 2.0 to 6.5 cm in diameter, peaking at 4.6 cm. Deep-seated tumors on initial CT scan were excluded from this series. Histologi cal diagnoses were glioblastoma multiforme (grade IV astrocytoma) in 51 cases and anaplastic astrocy toma (grade III astrocytoma) in 22.
Between July, 1985 and July, 1989 , patients were selected for IORT when the following criteria were fullfilled: a) histological finding of supratentorial malignant glioma (anaplastic astrocytoma and glio blastoma multiforme), b) age of 13-74 years, c) Karnofsky performance status of 70% or better, and d) CT finding of the enhanced tumor 6.5 cm or less in diameter and located away from the midline. The 41 cases without IORT (control group) and 32 with IORT (IORT group) are summarized in Table 1 .
The initial treatment for control group was a combination of subtotal or total resection, external irradiation, and chemotherapy with 1-(4-amino-2 methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3 nitrosourea hydrochloride (ACNU), while that for IORT group added intraoperative irradiation to the same modality as control group. Usually, IORT was performed with craniotomy again 1 week after tumor resection in a radioprotection room using a microtron (MM-22, Scanditronix AB, Husbyborg, Uppsala, Sweden; max. 10 Gy/min).10l When a re sidual tumor was revealed on CT scan after the ini tial surgery, this was removed as much as possible through the second craniotomy.
As shown in Fig.  1 , 10-50 Gy irradiation (< 30 Gy in 28 cases, mean 26.7 Gy) was delivered in one session perpen dicularly to the suspected residual tumor bed. The radiation field was determined to affect a level of 1-2 cm deeper than the tumor-resected surface, and was controlled by 2, 3, 4, 5, 6, 8, or 10 cm diam eter cones (secondary brass collimators), with 6 cm cones used most frequently.
The depth was in creased by greater microtron energies, as reported previously." External irradiation was begun 1 week after TORT for IORT group and after surgery for control group, using megavoltage x-ray equipment. Whole brain irradiation at a total dose of 30-61 Gy (mean 53.4 Gy in IORT group, 55.1 Gy in control group) in 25-30 fractions was given in 5 days/week over 5-6 weeks. ACNU (2 mg/kg body weight) was ad ministered via the ipsilateral carotid artery for 5-10 minutes at the start of external irradiation. In addi tion, ACNU was given intermittently at the same dosage every 2 or 3 months for at least 1 year.
IORT was repeated in 14 cases where follow-up CT scans demonstrated recurrence of the tumor at the primary site and the above mentioned criteria were fullfilled again.
All cases were followed up for a minimum of 12 months after initial treatment.
The survivals in the control and IORT groups were evaluated using the Kaplan-Meier method, and the statistical significance of the survival curves assessed with the Cox-Mantel and generalized Wilcoxon tests. Local tumor recurrence within 12 months of initial treatment was evaluated in the IORT group from the clinical course and sequential CT and magnetic resonance (MR) findings. Cases of death in the IORT group were retrospectively investigated using sequen tial CT and autopsy findings.
Fig. 2
Kaplan-Meier plots of survival probability for 41 control (1) and 32 TORT cases (2) with glioblastoma or anaplastic astrocytoma (upper, p < 0.01), and for 25 control (1) and 26 IORT cases (2) with glioblastoma (lower, p < 0.01).
Ticks represent patients who were still alive. 
Results

I. Survival
The survival rates at 24 and 36 months after initial treatment were 23.6 and 13.1 % (median survival 20.7 months) in the control group, and 57.1 and 33.5% (median survival 26.2 months) in the IORT group (Fig. 2 upper) . The differences in survival curves were significant at p < 0.01. Among the glioblastoma cases, the survival rates at 24 and 36 months after initial treatment were 23.7 and 14.6% (median survival 15.9 months) for the 25 cases in the control group, and 48.4 and 25.8% (median survival 22.4 months) for the 26 in the IORT group (Fig. 2  lower) . The differences in the survival curves were significant at p < 0.01. However, the survival rates at 24 and 36 months after initial treatment were 59.5 and 25.5% (median survival 26.5 months) for the 18 cases receiving IORT once, and 53.8 and 38.5% (me dian survival 24.8 months) for the 14 cases receiving IORT twice. There was no statistically significant cor relation in the survival curves. There were also no statistically significant correlations in the IORT group between survival rates and tumor localization, although smaller tumor sizes indicated longer sur vivals.
II. Tumor recurrence in the IORT group
The neuroradiological diagnosis of the tumor recurrence was defined as an increasing enhanced mass in the resected area (i) and in the previously uninvolved contiguous brain (ii). In 14 cases, the recurrence was histologically confirmed by biopsy during the 2nd IORT. Remission was seen in 34.4% (I 1 cases) and tumor recurrence in 65.6% (21 cases). The cumulative incidence of tumor recurrence at 3, 6, and 12 months after initial treatment was 12.5% (4 cases, i), 34.4% (9 cases, i and 2 cases, ii), and 65.6% (14 cases, i and 7 cases, ii), respectively. There was no significant relationship between the tumor recurrence and total radiation dose. How ever, CT scans showed marked peritumoral edema with midline shift in five cases more than 10 months after the first treatment, four of whom received TORT twice in addition to more than 50 Gy of ex ternal irradiation.
There were 20 cases of death in the IORT group. The tumor extent was classified based on serial CT findings as: local recurrence; ventricular infiltration; local regrowth into noncontiguous brain, sparing the 
III. Autopsies
Five glioblastoma cases in the IORT group under went autopsy. The results are summarized in Table  3 . In all cases, the histological features in the majori ty of the primary lesion sites were necrotic changes, probably corresponding to the target area of in traoperative irradiation. However, numerous tumor cells in the marginal zone of the primary lesion were frequently seen, probably developing continuously from the residual tumor cells outside the irradiated field, or resistant to the radiation dose. As shown in Fig. 3 (Case 3 in Table 3) , the histological features distinguished the necrotic area from the tumor cell zone, where a well-defined border was seen. This probably corresponded to the intraoperative tumori cidal dose although the minimal required dose could not be identified. Autopsy cases frequently demon strated tumor cells developing in the periventricular region and/or subarachnoid space. Cases with marked peritumoral edema on the last CT scan (Cases 1-3) showed no cerebral hemorrhage or prominent vessel necrosis. 
Discussion
The microtron provides a precisely controlled irradia tion field and volume. Therefore, clinical application of the microtron should be able to control local tumor.
However, current literature shows that results in the treatment of malignant glioma are still poor. A 50% survival rate over a 2-year period is difficult to exceed with malignant glioma.2'5"") Hochberg and Pruitt5) and Maire et al. " reported that local recurrence occurs within or close to the original tumor site in 90.9-98.5% of cases. There fore, tumor reduction surgery followed by IORT using the microtron should control local tumor recurrence with minimal adverse effects on the sur rounding normal tissue. Our IORT group, despite the small number of cases, demonstrated a signifi cant prolongation of survival time compared to the control group and previous reports.") Nevertheless, IORT has certain problems. The irradiated field can not be completely restricted to the residual tumor after surgery because an exact clinical determination of the extent of malignant glioma is almost impossi ble. The optimum tumoricidal radiation dose also re mains unclear. Therefore, external whole brain ir radiation is still necessary to control residual tumor cells.
Improvements in survival time can be achieved by a combination of surgery and external irradiation.'" Walker et al.") also discussed the effective radiation dose. More recently, Gutin et al.') reported in teresting effects in brachytherapy using a high-target dose of 30-150 Gy. However, higher radiation doses may not always achieve better results even if given to a limited area, since higher doses increase the deleterious effects, especially in the brainstem. In our IORT series, there were no serious induced complica tions such as fatal cerebral necrosis. However, a few cases receiving more than 50 Gy intraoperatively, in addition to a mean 53.4 Gy external irradiation, demonstrated a wide low-density area on CT scan and mental dullness.
At present, no method can define accurately the ex tent of an individual tumor.'' The extent of tumor cells is determined clinically based on the relation ship between CT and/or MR imaging and histological examination.') However, the tumor ex tent is the most important factor influencing tumor recurrence, because it determines the IORT field in order to avoid a high-target volume in the brainstem. In our experiences,"
IORT is a favorable manage ment method if the CT scan shows the malignant glioma locates near the brain surface and is small. Clinicopathological results suggest the intraoperative radiation dose per session is limited to no more than 30 Gy, although the most frequent dose ranges from 10 to 50 Gy (mean 26.7 Gy/session).
Matsutani et al.') reported that less than 20 Gy is safe.
Precise diagnosis of tumor recurrence or radiation necrosis is impossible from the clinical course and neuroradiological findings. We used serial CT ex amination in our follow-up study of tumor recur rence in the IORT series. This showed the regional tumor recurrence was 34.4% after 6 months in our series, while Maire et al.') reported 74.7% at 4-5 months after the initial treatment.
This suggests that IORT is quite effective for local tumor control. However, the significance of a 2nd IORT on the recurrent tumor, even if histologically proven, still re mains unclear. Our series showed survival was significantly longer in the IORT group than in the control group (p < 0.01). There was no significant difference between one and two-IORT cases, 
